• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senti Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    12/2/24 8:26:07 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    false0001854270NASDAQ00018542702024-12-022024-12-02

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event Reported): December 2, 2024

    Senti Biosciences, Inc.
    (Exact Name of Registrant as Specified in Charter)

    Delaware
    001-40440
    86-2437900
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification Number)

    2 Corporate Drive, First Floor
    South San Francisco, CA 94080
    (Address of Principal Executive Offices) (Zip Code)

    (650) 239-2030
    (Registrant's telephone number, including area code)

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
     
    SNTI
     
    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒



    Item 7.01.
    Regulation FD Disclosure.

    On December 2, 2024, Senti Biosciences, Inc. (the “Company”) issued a press release announcing initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (“AML”). SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing healthy bone marrow cells. A copy of the press release is attached hereto as Exhibit 99.1.

    The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

    Cautionary Note Regarding Forward Looking Statements

    This Current Report on Form 8-K and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company’s expectation about any or all of the following: timing of its clinical trials for SENTI-202; the timing of availability of data from the ongoing Phase 1 clinical trial of SENTI-202; as well as the ability of any product candidate to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data. Forward-looking statements can be identified by terms such as “will,” “intent,” “expect,” “plan,” “potential,” “would” or similar expressions and the negative of those terms. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although the Company believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncertainties include, among others, those risk and uncertainties described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 14, 2024, and in any other filings made by the Company with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this Current Report on Form 8-K, other than to the extent required by law.

    Item 9.01.
    Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.
    Description
    99.1
    Press Release issued by the Company on December 2, 2024, furnished herewith.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Senti Biosciences, Inc.
         
    Date: December 2, 2024
    By:
    /s/ Timothy Lu
       
    Timothy Lu, M.D., Ph.D.
       
    Chief Executive Officer



    Get the next $SNTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    10/14/2025$12.00Buy
    H.C. Wainwright
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    SEC Filings

    View All

    Senti Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    4/1/26 4:31:42 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Senti Biosciences Inc.

    SCHEDULE 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    3/31/26 5:58:16 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Senti Biosciences Inc.

    10-K - Senti Biosciences, Inc. (0001854270) (Filer)

    3/27/26 8:06:56 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Senti Bio with a new price target

    H.C. Wainwright initiated coverage of Senti Bio with a rating of Buy and set a new price target of $12.00

    10/14/25 8:53:29 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Laidlaw initiated coverage on Senti Bio with a new price target

    Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

    6/6/25 8:36:59 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Senti Bio with a new price target

    Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

    10/7/22 7:14:34 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 10,757 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Lu Timothy K covered exercise/tax liability with 80,666 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:30 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 1,384 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    2/3/26 4:17:23 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

    SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonstrates how Logic-Gated receptor designs can significantly improve the efficacy, precision, and safety of cell therapies by enabling immune cells to selectively eliminate tumor cells while sparing hea

    4/1/26 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

    SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing he

    3/23/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

    SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonstrates how Logic-Gated receptor designs can significantly improve the efficacy, precision, and safety of cell therapies by enabling immune cells to selectively eliminate tumor cells while sparing hea

    4/1/26 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

    SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing he

    3/23/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Senti Biosciences Inc.

    SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 12:38:17 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

    SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 11:52:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    View All

    Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

    Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

    4/10/25 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care